Researchers in the Boyacá region of Colombia have uncovered a genetic mutation associated with hereditary angioedema, a rare disease characterized by episodes of severe swelling in various body parts. This finding could have significant implications for understanding and treating the condition, not only in Colombia but also in the United States.

The study, conducted between 2022 and 2023, identified three genetic variants associated with hereditary angioedema. One of these variants is entirely new, not previously documented in scientific literature. The macroproject was funded by royalties from departments and involved collaborative efforts with several institutions, including the University of the Rosario and the Institute of Genetics of the National University, said a doctor specializing in scientific research.

A Genetic Breakthrough in Boyacá

The research team worked extensively in municipalities such as Tunja, San José de Pare, and Toca, as well as in Veredas de Soledad in the municipality of Paipa. They identified four families with hereditary angioedema, two of which shared the same genetic variant. In total, they found three different genetic variants of the gene, with two previously reported in scientific literature and a completely new.

“We were working with different populations in Boyacá, identifying families affected by genetic diseases. In our analysis, we found four families with hereditary angioedema, of which two shared the same genetic variant. In total, we identified three variants of the gene, two of them previously reported in the scientific literature and one completely new which led us to register it worldwide.”

— Dr. Arias

The study revealed an unusually high prevalence of the disease in Boyacá, with an estimated occurrence of 1 in 16,000 inhabitants, significantly higher than the global average of 1 in 50,000 to 80,000 people. This discovery underscores the importance of regional genetic studies and their potential to inform broader health policies.

Understanding Hereditary Angioedema

Hereditary angioedema is a rare genetic disease inherited from parents to children. It causes recurrent episodes of swelling in the face, hands, feet, and sometimes in the gastrointestinal tract. Unlike common allergies, the symptoms of hereditary angioedema do not respond to typical allergy treatments, such as antihistamines or corticosteroids.

The condition often might be mistaken for a common allergic reaction, delaying accurate diagnosis and treatment. In severe cases, swelling can obstruct the airway, posing a life-threatening risk to patients.

“One of the problems with this disease is that it is often confused with a common allergic reaction, which delays adequate diagnosis and treatment. In some cases, swelling can affect the airways and represent a vital risk for patients.”

— Dr. Arias

Implications for Health Authorities and Patients

The research team called on health authorities in the region to improve care for patients with hereditary angioedema. This includes ensuring the availability of specific treatments in healthcare centers near affected families. Medications are available both for managing acute episodes and for preventing new crises, but access remains limited in many areas.

“It is essential to guarantee the availability of specific treatments in health centers close to affected families. There are medications both for the management of acute episodes and for the prevention of new crises, but their access remains limited in many regions.”

— Dr. Arias

All areas with a concentrated population of genetic disorders would benefit from epidemiological surveillance. Strengthening epidemiological surveillance in Boyacá could help in the timely detection of more cases of orphan diseases, many which are just receiving public attention in the US. This strategy is vital considering that such discoveries can lead to proactive development of treatments and specifications around diagnosis.

*Due to a lack of sufficient details and latencies between international studies and time to market in the U.S., future breakthroughs and discoveries will remain subject to periodic synergy.*

Considerations for U.S. Healthcare

While the discovery in Colombia has significant implications, the U.S. healthcare landscape is not immune to the challenges posed by rare genetic diseases. The Centers for Disease Control and Prevention (CDC) reports that about 25 to 30 million Americans are affected by rare diseases, many of which lack effective treatments. This highlights the need for enhanced genetic research and more robust healthcare infrastructure to address these conditions.

The finding in Boyacá also underscores the importance of genetic epidemiology, a field that studies the distribution and determinants of genetic traits in populations. By understanding the prevalence and genetic variants of diseases, healthcare providers can develop more targeted and effective treatments. This could lead to the development of gene therapies, as seen in the recent approval of treatments for conditions like sickle cell disease and certain types of cancer.

In the U.S., the Orphan Drug Act of 1983 provides incentives for pharmaceutical companies to develop treatments for rare diseases. This act has led to the development of numerous therapies for conditions that were previously considered untreatable. However, the cost of these therapies often remains high, making them inaccessible to many patients. Addressing this disparity through public-private partnerships and healthcare policy reforms is critical.

Moreover, the rare disease community in the U.S. is increasingly advocating for comprehensive healthcare coverage and better access to experimental treatments. Examples of these groups include the National Organization for Rare Disorders (NORD) and Rare Disease United, which are working to raise awareness and promote research funding. International collaborations, such as the one in Boyacá, could accelerate the development of effective treatments and improve the quality of life for patients worldwide.

Recommendations and Future Directions

By following suit of the Colombian team, healthcare authorities across the globe should advocate for increased genetic research, enhance diagnostic capabilities for rare diseases, and scrutinize the environmental factors influencing these conditions. They must also focus on early identification, accurate diagnosis, and effective treatment of hereditary angioedema and other genetic disorders. This global approach would provide relief to orphan patients and localize rare conditions through targeted healthcare plans and development.

Genetic disorders, like hereditary angioedema, often go undiagnosed or misdiagnosed, leading to delays in treatment and potential severe health outcomes. Providing access to affordable genetic testing and early screening programs can significantly improve patient outcomes. Additionally, investing in genetic research and the development of new therapeutic options is crucial for managing these conditions effectively.